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BPTF is required for c-MYC transcriptional activity
and in vivo tumorigenesis
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c-MYC oncogene is deregulated in most human tumours. Histone marks associated with
transcriptionally active genes define high-affinity c-MYC targets. The mechanisms involved in
their recognition by c-MYC are unknown. Here we report that c-MYC interacts with BPTF, a
core subunit of the NURF chromatin-remodelling complex. BPTF is required for the activation
of the full c-MYC transcriptional programme in fibroblasts. BPTF knockdown leads to
decreased c-MYC recruitment to DNA and changes in chromatin accessibility. In Bptf-null
MEFs, BPTF is necessary for c-MYC-driven proliferation, G1–S progression and replication
stress, but not for c-MYC-driven apoptosis. Bioinformatics analyses unveil that BPTF levels
correlate positively with c-MYC-driven transcriptional signatures. In vivo, Bptf inactivation in
pre-neoplastic pancreatic acinar cells significantly delays tumour development and extends
survival. Our findings uncover BPTF as a crucial c-MYC co-factor required for its biological
activity and suggest that the BPTF-c-MYC axis is a potential therapeutic target in cancer.
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T
he MYC oncogenes encode a family of related sequence-
specific bHLHZip transcription factors (c-, L- and
N-MYC) that control a plethora of cellular functions
including cell growth, proliferation, differentiation and apoptosis.
c-MYC is deregulated in more than half of human cancers1, often
in association with aggressive, poorly differentiated tumours2.
The oncogenic potential of c-MYC stems from its function as a
transcriptional regulator that binds DNA on heterodimerization
with MAX3. MYC-MAX heterodimers show a predilection for the
palindromic ‘E-box’ motif (CACGTG) found in regulatory
elements of genes controlled by this complex4. Nonetheless,
mounting evidence indicates that the genomic distribution of
c-MYC-MAX complexes is influenced by factors other than
sequence specificity, most notably the chromatin context5,6.
High-affinity sites are bound by c-MYC in a wide variety of cell
types and are typically enriched in CpG islands together with high
levels of activating histone marks (H3K4me3, H3K79me, H3ac
and H2A.Z). Low-affinity sites vary among cell types and are only
engaged when c-MYC is expressed at high levels. Compared with
high-affinity targets, they show a selective enrichment for
macroH2A, H3K27me3 and H4K16ac5–7. Upon binding to its
target promoters, c-MYC recruits multiple cofactors that affect
the state of chromatin and the activity of RNA polymerases.
Among them are chromatin-remodelling complexes (for example,
SWI/SNF), acetyltransferases and methyltransferases that modify
core histones (for example, P300/CBP-Associated Factor (PCAF))
and proteins associated with the basal transcriptional machinery
(for example, P-TEFb)8–10.
The mechanisms involved in the recognition of the active
chromatin configuration by c-MYC are poorly understood but
likely involve the combined action of epigenetic ‘readers’ and
chromatin remodellers that modulate the accessibility of DNA in
modified nucleosomes. A plausible candidate to act as a c-MYC
tethering factor is NURF (ATP-dependent nucleosome-remodel-
ling factor), an ISWI complex that uses ATP hydrolysis to
catalyse nucleosome sliding11,12. Mammalian NURF consists of
three subunits: BPTF, SNF2L and pRBAP46/48. BPTF
(bromodomain PHD transcription factor) provides sequence
specificity to NURF through interactions with transcription
factors, histone variants and histone modifications of
transcriptionally active genes (H3K4me3, H4K16Ac and
H2A.Z)12–14. We found that BPTF is mutated in bladder
tumours and its knockdown in cultured bladder cancer cells
results in reduced proliferation15 and hypothesized that these
effects might be mediated, in part, by c-MYC.
Here we show that BPTF and c-MYC are present in a protein
complex. This interaction is critical for c-MYC function, since
BPTF knockdown leads to a decrease in c-MYC binding to DNA,
changes in chromatin accessibility and impaired activation of the
c-MYC transcriptional programme. Consistent with this, BPTF
expression in human tumours positively correlates with activation
of c-MYC gene signatures. In addition, BPTF is necessary
for the survival of c-MYC-overexpressing cells and for
c-MYC-driven tumorigenesis in the mouse pancreas. These
results highlight the potential of exploiting the BPTF-MYC axis
in cancer therapy.
Results
BPTF depletion impairs c-MYC transcriptional activity. To
assess whether BPTF is required for the transcriptional activity of
c-MYC, human foreskin fibroblasts (HFFs) were stably
transduced with the chimeric MYC-ER complementary DNA
(cDNA; hereafter HFF MYC-ER) and infected with lentiviruses
coding for either control (shNt) or BPTF-targeting short-hairpin
RNAs (shRNAs; sh#1 and sh#2). To rule out proliferation-asso-
ciated effects, and to avoid the interference of endogenous
c-MYC, cells were driven to quiescence by serum starvation
before treatment with 4-hydroxytamoxifen (4-OHT). Western
blot and immunofluorescence analyses confirmed that the lenti-
viral shRNAs inhibited the expression of BPTF and did not
interfere with either MYC-ER expression or nuclear translocation
(Fig. 1a; Supplementary Fig. 1a). We examined the expression
of a set of well-established c-MYC targets in control and
BPTF-silenced HFF MYC-ER cells by real-time quantitative
reverse transcriptase PCR (RT–qPCR). BPTF knockdown
resulted in a significant impairment of the induction of 6/7
c-MYC messenger RNA (mRNA) targets with at least one of the
two shRNAs (Fig. 1b; Supplementary Fig. 1b). To extend these
findings, we used Bptf-null mouse embryonic fibroblasts
(MEFs)16 transduced with MYC-ER. Successful recombination of
the floxed allele was demonstrated by PCR and RT–qPCR
analysis (Supplementary Fig. 1c,d). In these cells, addition of
4-OHT also resulted in an impaired activation of four c-MYC
targets tested17 (Supplementary Fig. 1e).
To further investigate the hypothesis that BPTF is required
for c-MYC-dependent transcription, we performed global RNA
profiling (RNA-Seq) using HFF MYC-ER cells. Normalization
with spike-in standards18 yielded B6,700 differentially
expressed genes in 4-OHT-treated control cells relative to
vehicle (Supplementary Data 1). Gene Set Enrichment Analysis
(GSEA) revealed that the genes upregulated upon 4-OHT
addition were significantly enriched in c-MYC-dependent
transcriptional signatures19–21 and gene ontology pathways
classically associated with c-MYC function (that is, ribosome
biogenesis and translation, mitochondrial function, and RNA/
ribosomal RNA/transfer RNA processing). Moreover, genes
downregulated in control 4-OHT-treated cells overlapped with
Figure 1 | BPTF is required for c-MYC transcriptional activity. (a) Immunofluorescence staining of BPTF and c-MYC showing MYC-ER nuclear
translocation upon 4-OHT treatment in control and BPTF-silenced HFF. Scale bar, 25mm (b) Examples of expression of known c-MYC target genes,
analysed by RT–qPCR, upon BPTF knockdown. Transcript levels were normalized against GAPDH and the vehicle-treated condition. Data are expressed as
mean±s.e.m. (nZ3). P values were determined using an unpaired t-test. (c) Fold change in FPKM values of c-MYC-dependent gene sets enriched in 4-
OHT-treated control cells. Values are displayed for both control and BPTF-silenced HFF MYC-ER cells. Gene sets tested and P values (Wilcoxon test): 1,
Schuhmacher et al. ‘MYC targets up’ (P¼ 3.156 10 15); 2, Acosta et al. ‘proliferation independent MYC targets up’ (P¼ 2.034 1008); 3, Schlosser
et al. ‘MYC targets serum response up’ (P¼6.62 1009); 4, Schlosser et al. ‘MYC targets serum response Dn’ (P¼6.11  1009); 5, Schlosser et al. ‘MYC
targets repressed by serum’ (P¼ 2.747  10 14). (d) Fold change in mRNA levels for the set of 20 genes used for validation. Left panel: data calculated from
FPKM values. Right panel: data calculated from Z3 independent experiments assessed by RT–qPCR. P values were determined using a Wilcoxon test.
(e) Examples of genes included in the validation. Transcript levels were normalized against GAPDH and the vehicle-treated condition. Data are expressed
as the mean±s.e.m. P value was determined using an unpaired t-test. (f) Co-immunoprecipitation of Flag-BPTF with HA-tagged c-MYC from lysates of
transiently transfected 293T cells; western blotting with the indicated antibodies. (g) Endogenous BPTF and c-MYC interact in MIA PaCa-2 cells as shown
by in situ proximity ligation assay. The interaction events are visible as red dots (nuclear staining in blue) and are marked by arrowheads. The interaction of
MYC with MAX is shown as a positive control. Number of dots per nuclei was quantified manually (n¼ 70 nuclei). Scale bar, 5 mm. *Po0.05; **Po0.01;
***Po0.001.
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gene sets known to be repressed by c-MYC22,23 (Supplementary
Fig. 1f; Supplementary Data 2). These findings are consistent
with the specific transcriptional regulation of the c-MYC
signature and validate the approach used.
BPTF knockdown in HFF MYC-ER cells resulted in a reduced
transcriptional response to 4-OHT, both up- and downregulated
genes being significantly affected (Supplementary Fig. 1g). The
mechanisms involved in c-MYC-mediated repression have not
been fully elucidated; therefore, we focused on its best-established
role as a transcriptional activator18. We found an impaired
activation of five independent c-MYC signatures in
BPTF-silenced cells (Fig. 1c). These results were validated by
RT–qPCR for an additional 20 genes, 19 of which are c-MYC
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in at least one cell line profiled by ENCODE (Supplementary
Data 1 and 3). The extent of induction of these genes was
significantly reduced in HFF MYC-ER cells transduced with
both BPTF-targeting shRNA lentiviruses (average fold change
(4-OHT versus vehicle) for shNt, 2.44; sh#1, 1.52; sh#2, 1.97;
shNt versus sh#1, Po0.001; shNt versus sh#2, P¼ 0.049;
unpaired t-test; Fig. 1d). Representative results are shown
in Fig. 1e. These data indicate that BPTF is required for
c-MYC-mediated gene regulation.
BPTF interacts with c-MYC. To activate transcription, c-MYC
recruits chromatin-modifying and -remodelling complexes that
hyperacetylate histones, displace nucleosomes and increase DNA
accessibility at target regions8,24,25. BPTF recognizes histone
marks present in both high- and low-affinity c-MYC
target promoters and is involved in chromatin remodelling.
We thus reasoned that BPTF association with c-MYC might
mechanistically explain the suppression on c-MYC transcription.
Immunoprecipitation of Flag-BPTF followed by western blotting
to detect HA-MYC from transfected 293T lysates revealed both
proteins in the same complex (Fig. 1f). The interaction between
endogenous c-MYC and BPTF was validated in MIA PaCa-2
pancreas cancer cells, expressing high levels of both proteins,
using the in situ proximity ligation assay (isPLA) and affinity-
purified rabbit antibodies recognizing BPTF residues 913–942
(Fig. 1g; Supplementary Fig. 2a,b). Together, these data suggest
that BPTF interacts with c-MYC.
BPTF regulates c-MYC binding to DNA. The E-box motif
recognized by c-MYC is very widely represented at the genome-
wide level and the findings described above suggested that BPTF
serves to recruit c-MYC to its target promoters through its ability
to recognize specific histone marks. To test this hypothesis, we
conducted ChIP with anti-c-MYC antibodies followed by massive
parallel sequencing (ChIP-Seq) in HFF MYC-ER cells
(Supplementary Data 4). A total of 1,397 peaks were identified in
4-OHT-treated control cells. In agreement with previous reports,
the analysis of the density profiles of the distance between the
summit of peaks and transcription start sites (TSSs) showed that
c-MYC-binding sites concentrate around the TSS (Supplementary
Fig. 3a)5,26. ChIP peaks occurred within promoter regions
(TSS±3 kb; 35.6%), gene bodies (intragenic; 25%) and further
upstream or downstream (intergenic; 39.4%). Sequence analysis
of c-MYC-bound regions with MEME27 unveiled a significant
over-representation of the MYC-MAX-binding motif
(P¼ 2.8 10 69; Supplementary Fig. 3b). Moreover, GSEA
analysis of c-MYC-bound promoters showed highly statistically
significant overlap with three transcriptional signatures of
c-MYC-dependent genes and with biological modules associated
with c-MYC function (for example, cell proliferation;
Supplementary Fig. 3c; Supplementary Data 5). Furthermore,
genes directly bound by c-MYC showed a significantly higher
mRNA induction than those lacking a ChIP-Seq peak
(Supplementary Fig. 3d).
To determine whether BPTF silencing interfered with c-MYC
recruitment to chromatin, we analysed the magnitude and
distribution of c-MYC ChIP-Seq peaks upon BPTF knockdown.
Globally, c-MYC-binding intensity was significantly lower in
shBPTF-expressing cells (Po2.2 10 16, Wilcoxon test)
(Fig. 2a,b). This reduction was not uniformly distributed at the
genome-wide level: only 50.2% of the peaks showed a read
number fold change Z2 and this was unrelated to peak intensity,
suggesting that the differences did not result from an inefficient
ChIP. These results indicate that BPTF silencing selectively affects
a subset of c-MYC ChIP-Seq peaks. We validated these
observations by ChIP–qPCR on gene promoters for which a
peak was identified in the ChIP-Seq experiment (‘target’), as well
as on ‘non-target’ control genomic regions (Supplementary Data
3 and 6), in at least three independent experiments. By this
approach, c-MYC recruitment to target genes was significantly
reduced in cells infected with the BPTF-targeting shRNAs
(Fig. 2c,d; Supplementary Fig. 3e).
c-MYC target regions cluster into ‘high-affinity’ or ‘low-
affinity’ sites. We investigated the effect of BPTF knockdown on
c-MYC recruitment to both types of targets, as previously
defined5,26, and observed a significant enrichment of high-affinity
sites among the genes less affected by BPTF silencing (Fig. 2e,f).
These data suggest that BPTF requirement for target recognition
by c-MYC depends on the epigenetic context: while dispensable
for c-MYC binding to H3K4me3-rich ‘high-affinity’ promoters, it
is necessary for c-MYC binding to low-affinity sequences,
possibly through the recognition of H4K16ac. The effect of
BPTF silencing on the induction of c-MYC target mRNAs was
independent from the extent of reduction in c-MYC binding at
their promoters (Fig. 2f; Supplementary Data 7), suggesting that
c-MYC requires BPTF to activate transcription at low-affinity
targets genes.
BPTF is required for c-MYC-induced chromatin remodelling.
To assess whether BPTF knockdown led to changes in DNA
accessibility, we performed quantitative DNAse I hypersensitivity
assays, as described earlier28. DNAse I hypersensitive sites mark
cis-regulatory elements (that is, enhancers or promoters) and
result from the cooperative binding of transcription factors and
chromatin-remodelling complexes29. We analysed the DNA
accessibility of c-MYC ‘target’ promoters validated in Fig. 2c, in
the presence or absence of 4-OHT, and included ‘non-target’
regions for comparison. 4-OHT addition to HFF MYC-ER cells
led to an increased sensitivity to DNAse I of ‘target’ regions in
control (Po0.001, paired t-test) but not in BPTF-silenced cells
(Fig. 3a (top); Supplementary Data 8). There was no consistent
effect on ‘non-target’ promoters (Fig. 3a (bottom) and
Supplementary Data 8). Overall, these results indicate that
attenuation of the c-MYC transcriptional response resulting
from BPTF knockdown is associated with changes in DNA
accessibility, suggesting that BPTF is necessary for the
c-MYC-induced remodelling of target chromatin. We next
analysed the levels of acetylated H3 and H3K4me3 in ‘target’
and ‘non-target’ promoters by ChIP–qPCR. As reported
previously, c-MYC activation in control cells was associated
with the selective hyperacetylation of histone H3 in ‘target’
promoters (P¼ 0.002, paired t-test). Importantly, this effect was
lost upon BPTF knockdown (Fig. 3b, top). By contrast, the levels
of H3K4me3 were unaffected by BPTF silencing (Fig. 3b, middle).
c-MYC activation in control cells was associated with a significant
decrease in total H3 at c-MYC target promoters, suggesting
chromatin remodelling. BPTF silencing did not alter the basal
levels of H3 at these sites but it impaired H3 depletion (Fig. 3b,
bottom), in agreement with the DNAse I hypersensitivity data. In
summary, these results indicate that BPTF regulates chromatin
accessibility at c-MYC target promoters.
BPTF is required for a subset of c-MYC biological functions.
MYC proteins regulate a wide variety of biological processes
including cell proliferation, differentiation and apoptosis.
Physiological c-MYC levels induce DNA synthesis through the
transcriptional activation of cell cycle-related genes30 and by
modulating the activity of DNA replication origins31. Here we
analyse the requirement of BPTF for c-MYC-induced
proliferation, replication stress and apoptosis.
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To determine whether BPTF is required for c-MYC-induced
proliferation, we used wild-type (WT) and Bptf-null MEFs. Cells
were co-infected with lentiviruses coding for Cre recombinase
and the MYC-ER fusion protein. Quiescent MEFs were induced
to re-enter the cell cycle by adding fetal bovine serum (FBS)±4-
OHT and S-phase entry was assessed by 5-bromodeoxyuridine
(BrdU) uptake. 4-OHT-treated WT and Bptf-null cells showed a
significantly higher percentage of cells in S-phase than vehicle-
treated cells as early as 9 h after FBSþ 4-OHT stimulation
(P¼ 0.014, paired t-test), indicative of MYC-induced G1/S
progression (Fig. 4a). DNA content analysis of BrdUþ cells
followed by quantification of cells in early S-phase showed that
BPTF deletion resulted in a significantly delayed progression
through S-phase in MYC-ER-activated cells (at 18 h, Po0.001,
unpaired t-test). There were no effects on vehicle-treated cells
(Fig. 4b,c).
c-MYC overexpression and/or deregulation is associated with
unscheduled firing of DNA replication origins, DNA damage
response and checkpoint activation32. In WT MYC-ER MEFs,
4-OHT addition led to an increase in the median signal intensity
of pan-nuclear gH2AX (P¼ 0.017, paired t-test), indicative of
replication stress. In Bptf-null cells, a slight increase was observed
in basal conditions but there was no significant change upon
addition of 4-OHT (Fig. 4d).
c-MYC can induce apoptosis when expressed from an ectopic
promoter in the presence of limiting survival signals or upon
stress33. To assess whether BPTF is required for MYC-induced
apoptosis, WT and Bptf-null MYC-ER MEFs were seeded at high
density and cultured in 0.5% FBS containing either vehicle or
4-OHT. Apoptosis was quantified by Annexin V staining and
4,6-diamidino-2-phenylindole (DAPI) exclusion. MYC-ER

































































































































































































































































































































Figure 2 | BPTF silencing interferes with c-MYC recruitment to its target genes. (a) Box plot showing the intensity of c-MYC ChIP-Seq signal (reads per
peak) at MYC-enriched regions in control and BPTF-silenced HFF MYC-ER cells. MYC-enriched regions were defined in 4-OHT-treated control cells.
c-MYC-binding intensity was measured as number of reads per peak. ***Po0.001 (Wilcoxon test). (b) Representative snapshots of c-MYC-bound genomic
regions in control and BPTF-silenced HFF MYC-ER cells after stimulation with 4-OHT. (c) ChIP analysis of c-MYC enrichment at the promoters of ‘target’ and
‘non-target’ genes in control and BPTF-silenced HFF MYC-ER cells in the presence (white) or absence of 4-OHT (black). ChIP values are expressed as
average±s.e.m. of % input chromatin. An isotype-matched IgG antibody was used as control (Supplementary Fig. 3f) and Z3 independent experiments were
analysed per promoter region. (d) Fold change in % of input following 4-OHT addition, averaged for the two different promoter populations in control and
BPTF-silenced cells. ***Po0.001 (unpaired t-test). (e) Groups A and B are defined as in f. High-affinity MYC targets are significantly enriched among the
genes for which MYC recruitment is less affected by BPTF knockdown. *Po0.05 (unpaired t-test). (f) c-MYC target genes ranked according to the change in
c-MYC binding at their promoters after BPTF silencing. BPTF dependency of c-MYC recruitment to DNA is calculated as the Log2 (reads shBPTF/reads shNt;
left y axis). For the same collection of ranked genes, the transcriptional response to 4-OHT is shown (scatter plot right y axis). BPTF dependency of
4-OHT-dependent mRNA induction is calculated as the Log2 (F.c. shBPTF/F.c. shNt). Four data points are outside the right y axis limits.
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and in Bptf-null MEFs (Fig. 4e), indicating that BPTF is
differentially required for a subset of c-MYC biological functions.
Deregulation of the c-MYC:BPTF axis in human cancer.
To gain insight into the role of the c-MYC:BPTF axis in human
cancer, we analysed public omics data sets. First, we compared
BPTF and c-MYC levels with the activation of c-MYC signatures
in a collection of 20 expression data sets from Oncomine and
Gene Expression Omnibus (GEO) encompassing human tumours
of diverse origin (Supplementary Data 9) driven by different
MYC family members: Burkitt lymphoma (BL), colorectal,
prostate and pancreatic tumours are mainly driven by
c-MYC34–36, whereas medulloblastoma and ovarian carcinoma
commonly show amplification and/or overexpression of N-MYC
and L-MYC, respectively37,38. BPTF is overexpressed in tumours
together with c-MYC and, in some cases, N-MYC and L-MYC
(Supplementary Fig. 4a). Samples within each data set were
rank-ordered by the mRNA levels of either BPTF, c-MYC,
N-MYC or L-MYC and then interrogated by single-sample GSEA
(ssGSEA)39 for enrichment of four c-MYC gene sets showing a
modest degree of overlap (Fig. 5a). c-MYC signatures correlated
with c-MYC expression levels in BL, colorectal, prostate and
pancreatic carcinomas. In these tumours, BPTF expression levels
also correlated positively with c-MYC signatures (Fig. 5b,c). By
contrast, N-MYC and L-MYC expression levels correlated with
c-MYC expression signatures only in medulloblastoma and
ovarian carcinoma, respectively, and in these tumours the
signatures correlated negatively with BPTF expression levels
(Fig. 5b,c). These data suggest that BPTF is more selectively
associated with the biological activity of c-MYC than with that of
N-MYC or L-MYC.
On the basis of these findings, we focused on tumour types
associated with c-MYC hyperactivation. First, we analysed the
expression of BPTF and c-MYC in the Cancer Cell Line
Encyclopedia data set. As shown in Fig. 6a, expression of both
genes was positively correlated across all tumour types. We then
selected BL and pancreatic ductal adenocarcinoma (PDAC) cells
for further analysis. BL is a paradigm of a c-MYC-addicted
human tumour resulting from chromosomal translocations
placing c-MYC under the control of Ig regulatory sequences
leading to c-MYC overexpression34. Consistently, BL-derived
lines are among the highest expressors of both BPTF and c-MYC.
PDAC-derived cell lines express intermediate levels of both genes
(Fig. 6a) and their dependency from c-MYC is generally
not the result of primary genetic alterations in this gene. BPTF
knockdown in NAMALWA and RAJI BL cells was accompanied
by reduced cell proliferation (Fig. 6b,c). Similarly, BPTF
knockdown in PK9 and MIA Paca-2 cells led to reduced
proliferation (Fig. 6d,e), indicating that tumour types with
different c-MYC dependency require BPTF to sustain
proliferation.
BPTF inactivation prolongs the survival of Ela1-Myc mice. On
the basis of the important role of c-MYC in cancer, the bioin-
formatics analyses, and results of knockdown experiments shown
above, we asked whether BPTF is also required for the oncogenic
effects of c-MYC in vivo using genetic mouse models. Because
there is increasing evidence that differentiation acts as a tumour
suppressor mechanism in the pancreas40,41, we first analysed
whether Bptf deletion in this tissue results in altered cell
differentiation. We analysed the pancreas of 8-week-old mice in
which Bptf was deleted at E9.5–E10.5 using Ptf1a-Cre as a deletor
strain. Very efficient recombination and downregulation
of the WT Bptf transcript was achieved (Fig. 7a). The pancreas
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Figure 3 | BPTF is required for MYC-induced chromatin remodelling.
(a) DNase I hypersensitivity (DHS) at MYC-bound regions in control and
BPTF-silenced HFF MYC-ER cells, determined by enzyme titration. Dots
represent the average values of seven independent experiments. P values
were determined using paired t-test. (b) ChIP analysis of Pan AcH3,
H3K4me3 and total H3 levels at the promoter of ‘target’ and ‘non-target’
genes in control and BPTF-silenced HFF MYC-ER cells. Each gene was
assayed in at least three independent experiments. ChIP values are
expressed as % of input and normalized for total histone H3 (with the
exception of total H3). P values were determined using paired t-test.
*Po0.05; **Po0.01; ***Po0.001.
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RT–qPCR analysis of acinar and endocrine markers failed to
reveal evidence of altered differentiation (Fig. 7b,c).
To determine the effects of Bptf deletion on tumour
development/progression, we used Ela1-Myc mice where
c-MYC overexpression is driven by the acinar-specific Elastase
1 promoter. These mice develop highly aggressive acinar
and ductal pancreatic tumours with a 100% penetrance42.
We generated Bptflox/lox;Ptf1a-CreERT2þ /KI;Ela-Myc mice
(BptfP / ;Ela-Myc) where BPTF can be depleted in PTF1Aþ
acinar cells at will. Tamoxifen was administered orally to
5–7-week-old mice, when dysplastic acinar cells are already
detectable. Oral administration of tamoxifen resulted in
recombination of 60–70% of the Bptf alleles as assessed by PCR
on genomic DNA (Fig. 7d). A cohort of BptfPþ /þ ;Ela1-Myc
(n¼ 10), BptfPþ / ;Ela1-Myc (n¼ 5) and BptfP / ;Ela1-Myc
(n¼ 8) mice was monitored weekly by ultrasound to determine
tumour-free survival and animals were killed when tumour
burden reached ethical end points or mice showed overt signs of
morbidity. BptfPþ /þ ;Ela1-Myc mice displayed the expected
course of pancreatic cancer onset, with a 50% disease-free
survival of 13 weeks42,43. In contrast, BptfPþ / ;Ela1-Myc and
BptfP / ;Ela1-Myc mice showed significantly delayed tumour
onset and a correspondingly delayed tumour progression
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Figure 4 | Bptf is required for MYC-induced proliferation of MEFs and replication stress but not for apoptosis. (a) WT (n¼4) and Bpft-null (n¼4)
MEFs transduced with MYC-ER were seeded at high density, arrested with 0.5% FBS for 48 h and stimulated with serum in the presence/absence of 4-
OHT. At the indicated time points, cells were pulse labelled with BrdU for 1 h before collected. Data are represented as mean±s.e.m. ***Po0.001 (paired t-
test). (b) Histograms depicting the ploidy of BrdU-positive cells throughout the experiment described in a. (c) Quantification of early S-phase cells. The
rate of loss of BrdUþ early S-phase cells represents S-phase progression. Data are represented as mean±s.e.m. *Po0.05; ***Po0.001 (unpaired t-test).
(d) Replication stress—intensity of gH2AX signal in WT and Bpft-null MYC-ER MEFs (n¼ 3 per group) in the presence or absence of 4-OHT for 48 h.
Doxorubicin-treated cells were used as control. *Po0.05 (paired t-test) (e) WT (nr4) and Bpft-null (nr4) MEFs expressing MYC-ER were seeded at high
density and then transferred to 0.5% FBS with or without 4-OHT (2mM). Apoptosis was measured as the proportion of Annexin V-postivive cells at the
indicated time points. *Po0.05; **Po0.01; ***Po0.001 (paired t-test to compare vehicle versus 4-OHT; unpaired t-test to compare WT versus Bptf-null
cells).
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tumorigenesis in these mice, we analysed tumour tissues obtained
at the time of death and evaluated by PCR the extent of
recombination at the Bptf locus: we found evidence of tumour
progression in both Bptf-deleted cells and in escaper cells in
which Bptf had not been deleted (Fig. 7g). In summary, these data
indicate that BPTF is necessary for the initiation and maintenance
of c-MYC-driven pancreatic tumours.
Discussion
The broad range of biological activities of c-MYC, its involvement
in a wide variety of human tumours, and its unique ability to
regulate a large fraction of the genome have spurred a great
interest in the study of the molecular mechanisms involved in the
c-MYC-mediated control of gene expression.
A prominent feature of c-MYC is that sequence-specific DNA
binding is only one of the requirements for its regulatory activity.
Its genomic distribution is influenced by the epigenetic context,
which is determined by histone modifications, histone variants
and CpG island distribution5,6. However, how these features
relate to c-MYC engagement to promoters is not known. Here
we provide evidence that BPTF interacts with c-MYC and
is a key determinant of its genomic distribution and biological
activity.
c-MYC target promoters can be classified according to their
binding affinity and histone marks. High-affinity sites display
high levels of H3K4me3, H2A.Z and unmethylated CpGs.
Low-affinity sites are enriched in repressive histone marks
(for example, H3K9me) together with H4K16Ac and are only
occupied when c-MYC levels are high5,6. BPTF can recognize
SCHUHMACHER et al.
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NES: Normalized enrichment score
Figure 5 | BPTF expression correlates with c-MYC signatures in human tumours. (a) Venn diagram showing the overlap of the c-MYC signatures used in
the following analyses. (b) Dot plot of normalized enrichment scores (NES) of the four c-MYC signatures based on GSEA. NES values were calculated for
each data set previously ranked-ordered by either BPTF or c-MYC levels. (c) Volcano plots of NES and enrichment P values of c-MYC signatures based on
GSEA. NES values were calculated for each data set previously ranked-ordered by BPTF, c-MYC, N-MYC or L-MYC mRNA levels. Filled circles represent
gene sets with a false discovery rate o0.25.
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histone marks in both types of promoters; however, low-affinity
promoters are more sensitive to BPTF levels. These results
support the hypothesis that protein–protein interactions between
c-MYC and other chromatin-bound complexes are critical to
target recognition by c-MYC44. BPTF binds H3K4me3 through
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Figure 6 | BPTF knockdown suppresses the proliferation of BL and pancreatic cancer cells. (a) Top: box plot showing the relative BPTF mRNA
levels across the different tumour types, extracted from CCLE_Expression_Entrez_ID_2186, with gene-centric robust multiarray analysis-normalized
mRNA expression data. Bottom: box plot showing the relative c-MYC mRNA levels across a panel of human cell lines, extracted from
CCLE_Expression_Entrez_ID_4609. The number of cell lines of each tumour type analysed is indicated in parentheses. Effective knockdown of BPTF in BL
cells (b) and pancreatic cancer cells (d), assessed by RT–qPCR. Transcript levels were normalized against GAPDH and the sh-control samples. Proliferation
analysis of two BL cell lines (NAMALWA and RAJI; c) and two pancreatic cancer cell lines (d) transduced with either control (shNt) or BPTF-targeting
shRNAs (sh#1 and #2) (n¼ 5). *Po0.05; **Po0.01; ***Po0.001.
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of this histone mark at c-MYC target promoters. By contrast,
BPTF silencing reduces the hyperacetylation of H3, commonly
associated to c-MYC activation46. These data suggest that BPTF,
either on its own or through its association with c-MYC, is
required to recruit and/or modulate the activity of histone
acetyltransferases (HATs) or histone deacetylases at promoters.
Precedents for this kind of regulation are found in Drosophila
melanogaster, where Nurf301 is needed for the histone
acetyl-transferase ATAC to access chromatin and maintain the
decondensed architecture of the male X chromosome47. More
work is required to determine how BPTF regulates the
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Figure 7 | BPTF is dispensable for pancreatic differentiation but its inactivation delays the onset and progression of c-MYC-driven pancreatic tumors.
(a) PCR on genomic DNA showing efficient recombination at the Bptf locus in BptfP/ pancreas (top). RT–qPCR analysis of BPTF WT and mutant mRNA
species in control (n¼6) and BptfP/ (n¼ 7) mice (bottom). Transcript levels were normalized against actin and the WT condition. (b) Haematoxylin–
eosin staining of WT and BptfP/ mouse pancreatic sections. D, duct; V, blood vessel; *, islet of langerhans. Scale bar, 200mm. (c) mRNA expression of
acinar transcription factors, digestive enzymes and endocrine markers in pancreata of WT and BptfP/ mice assessed by RT–qPCR (n¼ 3 per genotype).
Transcript levels were normalized against actin and the WT condition. (d) PCR on pancreas (P) genomic DNA assessing the extent of recombination at the
Bptf locus in 5–7-week-old Ptf1a-CreERT2þ /KI;Ela-Myc mice of the corresponding genotypes. Liver (L) samples were used as negative controls.
(e) Kaplan–Meier curves of tumour-free survival are shown for Ela-Myc mice of the indicated Bptf genotypes. *Po0.05 (log-rank test). (f) Tumour volume
of Ela-Myc mice of the indicated Bptf genotypes as determined by ultrasound. Data are expressed as the mean±s.e.m. ****Po0.00001 (Wilcoxon test).
(g) PCR analysis of genomic DNA from tumours arising in BptfPþ/þ , BptfP/þ and BptfP/ ; Ela-Myc mice.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10153
10 NATURE COMMUNICATIONS | 7:10153 | DOI: 10.1038/ncomms10153 | www.nature.com/naturecommunications
BPTF silencing not only affected the transcriptional
response of promoters where c-MYC binding was reduced but
also of those where recruitment was unaffected. We propose that
this results from defective chromatin remodelling, as suggested
by the fact that BPTF silencing blocks the increase in
DNA accessibility at c-MYC promoters typically linked to
c-MYC activation. c-MYC recruits the chromatin remodeller
SWI/SNF8, whose activity is partially inhibited by the linker
histone H1 (ref. 48). NURF is necessary for H1 displacement at
the promoters of progesterone receptor target genes13. Thus, we
hypothesize that NURF-mediated eviction of H1 is a
pre-requisite for subsequent remodelling and nucleosome
eviction by SWI/SNF. Moreover, BPTF may either prevent or
enhance the binding of transcription factors to DNA sequences
adjacent to CCCTC-Binding Factor (CCTC)-binding sites.
For example, the binding of KLF4 in the vicinity of CTCF
sites is prevented by BPTF due to its nucleosome-remodelling
activity49.
The recognition of active histone marks in regions of open
chromatin by BPTF may facilitate and stabilize c-MYC binding.
However, alternative scenarios are possible and the mechanisms
through which c-MYC co-factors operate may differ at high- and
low-affinity promoters. Our studies do not allow us to conclude
on the sequence of recruitment of BPTF and c-MYC to target
promoters. This is, in part, due to the fact that the use of RNA
interference leads only to a partial reduction of BPTF levels.
Therefore, it is possible that—when present at low levels—BPTF
could differentially bind to histone marks and thereby affect gene
expression.
Recently, WDR5 and c-MYC have been shown to interact
directly. A c-MYC-WBM mutant unable to bind WDR5 showed
reduced chromatin recruitment capacity, suggesting that WDR5
is important for c-MYC binding to chromatin10. A direct
comparison of BPTF and WDR5 is required to determine the
specific role of each of these proteins in the regulation of c-MYC
activity.
The impact of BPTF silencing on c-MYC recruitment to distal
enhancer elements remains to be determined. Active enhancers
are characterized by high H3K4me1–2, H3K27ac, recruitment of
the HAT p300 and the presence of transcription factor-binding
motifs and DNAse I hypersensitivity sites50–52. The C-terminal
PHD finger of BPTF binds H3K4me2 (ref. 53). It is thus possible
that NURF is recruited to enhancers through H3K4me2, along
with other chromatin remodellers such as CHD7 and BRG1
(refs 54,55). Furthermore, as indicated above, BPTF interacts with
CTCF that can bind and regulate nucleosome distribution at
enhancers49.
c-MYC has a wide range of biological activities determined, in
part, by its expression levels. Therefore, we asked for which of
them is BPTF required. In multiple cell types, we show that
BPTF is essential for c-MYC-driven proliferation. However, it is
not necessary for MYC-triggered apoptosis in MEFs. Omomyc,
a c-MYC mutant protein that cannot dimerize with MAX and
does not bind E-boxes, also displays selective effects on c-MYC
function: it interferes with proliferation but it exacerbates
apoptosis triggered by high c-MYC levels56,57. The selective
effect of BPTF knockdown on a subset of c-MYC functions
could be related to the mechanisms of transcriptional activation
of the genes involved. To induce cell proliferation, c-MYC binds
directly the promoter of genes participating in DNA replication
and cell cycle control (that is, MCM5, MCM6 or DBF4) and
enhances their transcription26. By contrast, c-MYC-driven
apoptosis is mostly indirect, through pathways that do not
require binding to DNA, and involves the stabilization of
p19ARF and p53 or the downregulation of anti-apoptotic BCL-2
through inhibition of MIZ-1 (ref. 58). We therefore propose that
BPTF is only required for those c-MYC functions involving
direct binding to chromatin.
MYC oncogenes have partially overlapping biological functions
but display distinct tissue-specific expression and transforming
activity59. c-MYC and N-MYC can functionally replace one
another in certain contexts (for example, murine development)
and share similar oncogenic potency60,61, but N-MYC is
distinctly involved in the regulation of genes involved in neural
development62. Despite that less is known on L-MYC, it appears
to differ from the other family members22. Our genomic analyses
suggest that BPTF may differentially affect the oncogenic activity
of MYC family members and BPTF levels correlate positively
with a c-MYC transcriptional signature. CTCF is required for
c-MYC expression63; it is possible that BPTF and CTCF interact
to activate c-MYC expression through the recruitment of
transcription factors to its promoter. More work is required
to determine the relevance of the epigenetic context of,
and the requirement of BPTF for, the activity of N-MYC
and L-MYC.
In recent years, genetic mouse models have shown
that tumours become addicted to c-MYC64. In inducible
c-MYC-driven models, established tumours regress upon
withdrawal of ectopic c-MYC expression65. Even transient
inactivation of MYC is sufficient to restore checkpoint
mechanisms resulting in tumour regression, remodelling of the
tumour microenvironment, and shutdown of angiogenesis56.
These studies also show that systemic c-MYC inhibition in mice
causes a mild and reversible toxicity in proliferative tissues. On
the basis of these findings, we analysed whether the in vivo
oncogenic effects of c-MYC are dependent on BTPF using the
Ela-Myc model of pancreatic cancer. KRAS is the main oncogene
involved in human PDAC; however, c-MYC is amplified and
overexpressed in 10% and 450% of human PDAC,
respectively66. The relevance of c-MYC to pancreatic
carcinogenesis has been underscored by the finding that, in
mice, c-MYC is required for mutant KRas-driven development of
preneoplastic pancreatic lesions and invasive tumours67. In Ela-
Myc mice, dysplasia is observed at 8 weeks of age and multifocal
tumours develop starting a few weeks later; acinar tumours
occur early while ductal tumours—reminiscent of human
PDAC—appear later42,43. In this highly aggressive model,
elimination of a single Bptf allele was sufficient to delay tumour
initiation (that is, dysplasia) and progression. Importantly, these
effects did not result from an incomplete maturation of exocrine
cells—as in other systems—since we did not find evidence of
altered acinar differentiation in BptfP / mice, as determined
by histological analysis and digestive enzyme mRNA
expression. These findings support the notion that disruption of
the BPTF-c-MYC interaction may represent a valuable strategy
for the therapy of c-MYC-driven tumours. In this regard, it is
noteworthy that incomplete inactivation of Bptf in acinar cells
contributed to tumour development in a fraction of mice.
The mechanisms through which Bptf inactivation suppresses
MYC-driven tumour development in vivo need to be studied
further.
Despite the in vivo genetic evidences, a therapeutic approach to
target c-MYC has remained elusive. Unlike other transcription
factors, c-MYC lacks a ligand-binding domain, what constitutes a
formidable obstacle towards direct inhibition. Recently, the
disruption of chromatin-dependent processes that suppress
c-MYC activity—such as the inhibition of the BET bromodomain
protein Brd4 by JQ1—has shown promising results in
experimental models of multiple myeloma, BL, acute
myeloid leukaemia, acute lymphoblastic leukaemia and
neuroblastoma68,69. However, it is predicted that the effects of
these inhibitors would be restricted to tumours where c-MYC
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transcription is dependent on BRD4. We have shown that BPTF
is required for cell proliferation of BL, PDAC and bladder cancer
cells in vitro. The broad pattern of expression of BPTF in tissues70
and the correlation between BPTF expression and c-MYC
signatures in human tumours suggest that a wide range of
tumour types might be amenable to the therapeutic disruption of
the c-MYC-BPTF axis. We therefore propose that small
molecules capable of disrupting this interaction may represent a
valuable approach to treat c-MYC-addicted tumours.
To conclude, we have identified BPTF as an important cofactor
required for the full deployment of the biological activity of
c-MYC in vitro and in vivo, including its oncogenic effects.
Methods
Generation of polyclonal anti-BPTF anti-sera. The RLHRMTSIEREEKEKVK-
KKEKKQEEETC peptide (residues 913–942) was chemically synthesized, coupled
with keyhole limpet haemocyanin (KLH), and used as immunogen for the
generation of polyclonal antibodies against BPTF. Two rabbits were inoculated
subcutaneously with 500 mg of peptide–KLH conjugate emulsified in Freund’s
complete adjuvant. Five rounds of 250 mg peptide–KLH boosters were administered
together with Freund’s incomplete adjuvant to each animal in the interval
of 3 weeks. Antibodies against BPTF were purified from serum by affinity
chromatography on a HiTrap NHS-activated High Performance column
(Sigma-Aldrich, GE17-0716-01, St Louis, MO, USA) and tested by enzyme-linked
immunosorbent assay, in HEK293T-BPTF-Flag-transfected cells and in
BPTF-silenced VM-CUB-3 cells. Uncropped western blots are provided in
Supplementary Fig. 5.
Cell culture. Primary neonatal HFFs (a kind gift of M. S. Soengas, CNIO, Madrid,
Spain), 293T (transformed human embryonic kidney cells, from ATCC, Rockville,
MD, USA) and human adherent cancer cells—MIA PaCa-2 (from ATCC), PK9
(pancreas, from C. Iacobuzio-Donahue, Memorial Sloan-Kettering Cancer
Center, New York, NY, USA) and VM-CUB-3 (bladder, L. J. Old, Memorial
Sloan-Kettering Cancer Center)—were cultured in DMEM (Sigma-Aldrich)
supplemented with 10% FBS (HyClone, Logan, UT, USA), sodium
pyruvate (Life Technologies, Madrid, Spain) and penicillin/streptomycin
(Life Technologies). Mouse Bptfþ /þ and Bptflox/lox MEFs were cultured in
DMEM supplemented with 10% FBS, sodium pyruvate, non-essential amino
acids (Life Technologies), b-mercaptoethanol (Sigma-Aldrich) and penicillin/
streptomycin. NAMALWA and RAJI cells (from ATCC) were cultured in
suspension in RPMI medium (Sigma-Aldrich) supplemented with 10% FBS
and penicillin/streptomycin.
MEFs were generated by mechanical disruption and trypsin digestion of E13.5
embryos from which the fetal liver and the head had been removed. Recombination
efficiency of exon 2 upon Cre recombinase expression was evaluated by PCR on
genomic DNA as reported elsewhere1 (Supplementary Fig. 1c). The following
primers were used: 50-CTCAGGAATTAAGAGGTAATTGACTATC-30 , 50-TG
ATTTAGTTCTGATTGTTAGGTCTAC-30 and 50-AGACCAGCCTGTTCTACAT
GGCCAGCC-30 .
Animal experiments. The following mouse strains were used: Bptflox/lox (ref. 16),
Ptf1a-Cre (ref. 71), Ptf1a-CreERT2þ /KI (ref. 72) and Ela1-Myc (ref. 42). C57BL/6
Bptflox/lox mice were obtained from Jackson Laboratories (stock number 009367).
Other strains were available at CNIO.
To inactivate Bptf to analyse its role in c-MYC-driven pancreatic tumorigenesis,
we administered 25 mg of tamoxifen (Sigma-Aldrich, T-5648) by gavage over the
course of 1 week to 5–7-week-old Bptflox/lox;Ptf1a-CreERT2þ /KI;Ela1-Myc mice
and their corresponding controls. Mice were screened for pancreatic tumours once
a week using a small animal ultrasound system.
Mice were housed under specific pathogen-free conditions according to
institutional guidelines. Mice were observed on a daily basis and killed when
they showed signs of morbidity or tumour burden was 410% body weight in
accordance with the Guidelines for Human Endpoints for Animals Used in
Biomedical Research. All experiments were performed in accordance with the
guidelines for Ethical Conduct in the Care and Use of Animals as stated in The
International Guiding Principles for Biomedical Research involving Animals,
developed by the Council for International Organizations of Medical Sciences
(CIOMS), and were approved by the Instituto de Salud Carlos III Ethical
Committee.
Plasmids and lentiviral infections. Mission shRNAs (Sigma-Aldrich) were
used for RNA interference. Two BPTF-targeting shRNAs (shBPTF-1, clone
TRCN0000016819; shBPTF-2, clone TRCN0000016820) were used and compared
with a control non-targeting shRNA. MYC-ER was expressed from the cDNA
cloned in FG12 plasmid. For lentiviral transduction of Cre recombinase, we used
the lentiviral vector pLVXpuro-iCRE-ORF, a gift from C. Bar and M.A. Blasco
(CNIO).
Infectious lentiviruses were produced in 293T cells by calcium phosphate-
mediated transfection of the lentiviral construct together with the packaging
plasmids psPAX2 and pCMV-VSV-G. Post transfection (48 h), the medium was
collected twice for an additional 48 h. Viral supernatants were filtered and either
frozen down in aliquots or applied on target cells in the presence of 5 mg ml 1
polybrene. Cells were used after 48 h puromycin selection (2 mg ml 1). Human
fibroblasts were infected first with lentivirus coding for MYC-ER, expanded and
then infected with either control or BPTF-targeting shRNAs. MEFs were infected
concomitantly with lentivirus encoding for MYC-ER and Cre recombinase.
Viability assays of BL cell lines. BL cells (3 105 cells per well) were seeded on
plastic plates coated with retronectin (Fisher Scientific, Pittsburgh, PA, USA) and
preloaded with viral supernatants. After three additional rounds of infection
with viral supernatants supplemented with polybrene (8 mg ml 1), cells were
allowed to recover for 24 h, then selected for 48 h in puromycin-containing
medium (2 mg ml 1). After selection, cells (sh#1, sh#2 and shNT) were plated
(5 103 per well in 96-well plates) in replicates. Viable cell count was assessed
at the indicated time points by adding WST1 cell proliferation reagent (Roche,
Basel, Switzerland) to each well and determining OD450 nm after 2 h, according
to the manufacturer’s instructions.
Co-immunoprecipitation analyses. 293T cells transiently transfected with the
corresponding plasmids were washed twice with ice-cold PBS and lysed for 30 min
on ice with NP-40 lysis buffer (50 mM Tris:HCl pH 8.0, 150 mM NaCl and 1.0%
NP-40) supplemented with a protease inhibitor cocktail. Lysates were then
centrifuged at 16,000g for 20 min at 4 C. Total protein (1 mg) was incubated
with primary antibody (2mg) overnight. Protein A/G agarose beads (Laboratorios
Conda, Madrid, Spain) preblocked with bovine serum albumin (BSA) were then
added to the lysates. Following 4-h incubation at 4 C, beads were washed three
times with NP-40 lysis buffer and immunoprecipitated proteins were eluted with
SDS sample buffer by boiling at 90 C. SDS–polyacrylamide gel electrophoresis was
then performed on 6 and 10% (w/v) gels and proteins were then transferred onto
nitrocellulose membranes.
Western blotting. Cells were lysed in RIPA buffer supplemented with protease
and phosphatase inhibitors. Following sonication, clearing by centrifugation, and
protein determination, equal amounts of protein per sample were subjected to
electrophoresis in 8 or 10% polyacrylamide SDS gels, or in NuPAGE 3–8%
Tris-acetate precast polyacrylamide gels (Life Technologies). Samples were run
under reducing conditions and then transferred to nitrocellulose membranes,
which were blocked with TBST, 5% skim milk. Membranes were subsequently
incubated with the following primary antibodies: BPTF (1:500; ab72036, Abcam,
Cambridge, UK), c-MYC (1:500; 06–340, Millipore, Billerica, MA, USA) and
Vinculin (1:2,000; V9131-2ML, Sigma-Aldrich). This was followed by incubation
with horseradish peroxidase-conjugated secondary antibodies (1:10,000; Dako,
Glostrup, Denmark). Reactions were detected using the ECL system.
Immunofluorescence staining and isPLA. Cells grown on coverslips were fixed
with 4% paraformaldehyde for 10 min, washed and permeabilized with 0.1% Triton
X-100 in PBS for 10 min. Samples were washed in PBS and blocked with 3% BSA in
PBS for 1 h at room temperature. Primary antibody incubation was performed in
blocking solution for 2 h at room temperature. Mouse anti-MYC (C-33, sc-42,
Santa Cruz Biotechnology, Dallas, TX, USA) was used at a 1:50 dilution and
home-made affinity-purified rabbit anti-BPTF antibodies were used at 10 mg ml 1.
After three washes with PBS, cells were incubated with an appropriate secondary
antibody diluted in blocking solution. Nuclei were counterstained with DAPI and
coverslips were mounted on ProLong (Life Technologies). Images were taken with
a confocal microscope, using a  40 immersion oil lens. For the isPLA, the
DuolinkII fluorescence system was used (Olink Bioscience, Uppsala, Sweden).
Quantitative real-time PCR. Total RNA was isolated from cultured cells using the
GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich) according to
manufacturer’s instructions. Samples were treated with DNase I before reverse
transcription (Life Technologies). cDNA was generated from 1 mg of RNA using
random hexamers and reverse transcriptase. Real-time PCR amplification and
analysis was conducted using the 7900HT Real-Time PCR System (Applied
Biosystems, Life Technologies). RNA levels were normalized to GAPDH expression
using the DDCt method. For RT–qPCR analysis, primer pairs were designed to
achieve product lengths of 200–250 bp. Primer sequences are provided in
Supplementary Data 3.
FACS analysis of proliferation and apoptosis. For cell cycle analysis, cells
were pulse labelled with 10 mM of BrdU (Sigma-Aldrich) for 1 h, collected by
trypsinization and then fixed in 100% ethanol. Upon DNA denaturation using 2 N
HCl, cells were stained with mouse anti-BrdU primary antibody (sc-51514, Santa
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Cruz Biotechnology; 1 mg per 106 cells) and anti-mouse Alexa Fluor 488-conjugated
secondary antibody (A21202, Life Technologies; 1 mg per 106 cells). DNA was
stained by resuspending cells in 0.1 mg ml 1 of propidium iodide and incubating
for 30 min at room temperature until fluorescence-activated cell sorting (FACS)
analysis.
To measure apoptosis, MEFs were seeded at high density and then transferred
to 0.5% FBS-containing DMEM in the presence of either vehicle (EtOH) or 2 mM
4-OHT. At the indicated time points, cells and supernatants were collected, washed
and resuspended in Annexin V-binding buffer containing 5 ml per sample of
Annexin V-APC (550474, BD Biosciences, Franklin Lakes, NJ, USA). DAPI was
added before analysis.
All samples were analysed using a FACS Canto II (BD Biosciences) flow
cytometer. At least 10,000 events were acquired. Analyses were performed using
FlowJo flow cytometry anaysis software.
Chromatin immunoprecipitation. Cells were fixed with 1% formaldehyde for
15 min at room temperature. Fixation was stopped by adding glycine (to 0.125 M)
with an additional incubation of 5 min. Cells were collected by scraping, pelleted
and then lysed for 10 min in 1 ml of buffer LB1 (50 mM HEPES (pH¼ 7.5),
140 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.25% Triton X-100 and 10% glycerol)
supplemented with protease inhibitors (Qiagen, Valencia, CA, USA). After
centrifugation at 3,000g, pelleted nuclei were resuspended in 1 ml of buffer LB2
(10 mM Tris (pH¼ 8.0), 200 mM NaCl, 0.5 mM EGTA and 1 mM EDTA), and
incubated at room temperature for 10 min. Pelleted nuclei were resuspended in
1 ml of ChIP SDS buffer (100 mM NaCl, 50 mM Tris (pH 8), 5 mM EDTA pH 8,
0.2% NaN3 and 0.5% SDS) and sonicated for 20 min in a Covaris sonicator, yelding
DNA fragments of 300–500 bp. Beads were blocked overnight in PBS with 0.5%
BSA and then added to the samples. After a 3-h incubation at 4 C, beads were
washed with Triton dilution buffer (100 mM Tris (pH¼ 8.6), 100 mM NaCl, 5 mM
EDTA (pH¼ 8), 0.2% NaN3 and 5% Triton X-100), mixed micelle wash buffer
(150 mM NaCl, 20 mM Tris (pH 8), 5 mM EDTA (pH 8), 5% sucrose, 0.2% NaN3,
1% Triton X-100 and 0.2% SDS), Buffer 500 (0.1% deoxycholic acid, 1 mM EDTA
(pH¼ 8), 50 mM HEPES (pH¼ 7.5), 1% Triton X-100, 500 mM NaCl and 0.2%
NaN3), LiCl buffer (0.5% deoxycholic acid, 1 mM EDTA (pH 8), 250 mM LiCl,
0.5% NP-40, 10 mM Tris (pH¼ 8) and 0.2% NaN3) and Tris-EDTA (TE). DNA
was eluted in elution buffer and crosslinks were reversed by incubation overnight at
65 C. RNA and protein were digested using RNase A and Proteinase K and DNA
was purified by phenol–chloroform extraction and isopropanol precipitation.
Target DNA abundance in ChIP eluates was assayed by qPCR with primer pairs
designed to achieve products of 50–200 bp. Primer sequences are provided in
Supplementary Data 3. The following antibodies were used: anti-MYC N262
(sc-764, Santa Cruz Biotechnology), anti-H3K4me3 (ab8580, Abcam), anti-panAc
Histone H3 (06–599, Merk Millipore) and anti-Histone H3 (ab1791, Abcam).
DNase I hypersensitivity assay. Chromatin samples were subjected to DNAse I
digestion. Chromatin (2 mg) was treated with 0.5, 1 and 2 units of RQ1 RNase-Free
DNAse I (Promega, Fitchburg, WI, USA) for 3 min at 37 C in 1 DNAse
incubation buffer. Reactions were terminated by adding 2 mM EGTA and the
crosslinking was reversed by incubating samples at 65 C. After 6 h, proteinase K
(40 mg ml 1) was added to each reaction and incubated overnight at 37 C. After
phenol–chloroform extraction, DNA was quantified and used as template for qPCR
reactions with the same primer pairs used for ChIP–qPCR.
ChIP-Seq libraries and massive parallel sequencing. ChIP was performed
as described above. DNA (20 ng) was quantified by fluorimetry, resolved by
electrophoresis and fractions of 50–250 bp were extracted. Input samples
correspond to balanced blends of inputs from selected samples. Fractions were
processed through subsequent enzymatic treatments of end repair, dA tailing
and ligation to adaptors following Illumina’s ‘TruSeq DNA Sample Preparation
Guide’ (part #15005180 Rev. C). Adaptor-ligated libraries were amplified by
limited-cycle PCR with Illumina PE primers (12 cycles). The resulting purified
DNA library was applied to an Illumina flow cell for cluster generation (TruSeq
cluster generation kit v5) and sequenced on the Genome Analyzer IIx with SBS
TruSeq v5 reagents following the manufacturer’s protocols.
ChIP-Seq data processing. Image analysis and per-cycle base calling was
performed with Illumina Real Time Analysis software (RTA1.13). Conversion
to FASTQ read format with the ELAND algorithm (v2e) was performed with
CASAVA-1.8 (Illumina). Quality check was done via fastqc (v0.9.4, Babraham
Bioinformatics). ChIP-Seq reads were aligned to the human reference genome
(GRCh37/hg19, February 2009) with Burrows-Wheeler Aligner (v0.5.9-r16)
allowing 0–1 mismatches. Unique aligned reads were converted to BED format
(Supplementary Data 4). All ChIP and input samples were normalized randomly
to the same number of reads (10,512.988). Furthermore, reads were directionally
extended to 300 bp and, for each base pair in the genome, the number of
overlapping sequence reads was determined and averaged over a 10-bp window
to create a wig file to visualize the data in the University of California Santa
Cruz genome browser. The number of significant peaks of MYC-binding sites
was 1,762 for sh#1þOHT and 1,397 for shNtþOHT, using MACS (version
2.0.9 20111102, tag:alpha) and parameters:  g 2.7e9; m 10,30;  q 0.05.
Motif-enrichment analysis. Motifs for the list of peaks in shNtþOHT were
identified with the MEME suite and then TOMTOM was used to compare the
identified motifs with known transcription factor-binding motifs. Sequence logos
were generated using WebLogo 2.8.2.
Peak annotation and density plot analysis. Genomic annotation was carried out
with Hypergeometric Optimization of Motif EnRichment (software v4.2). The tool
annotatePeaks.pl was used with parameters by default and defined in the help. A gtf
file from University of California Santa Cruz based on GRCh37/hg19 was used for
annotations; the latter included whether a segment is in the TSS, transcription
termination site, exon, 50-untranslated region (UTR) exon, 30-UTR exon, intron or
is intergenic. Since some annotations overlap, the following priority was assigned:
TSS (from  1 kb to þ 100 bp), transcription termination site (from  100 bp
to þ 1 kb), protein coding exon, 50-UTR exon, 30-UTR exon, intron and intergenic.
More detailed information is available in http://homer.salk.edu/homer/ngs/
annotation.html. The SeqMINER (v1.3.3e) platform73 was used to generate
the density read plots shown in Supplementary Fig. 3a.
Gene Set Enrichment Analysis. MYC-bound genes were rank-ordered
according to the fold change in FPKM (fragments per kilobase of exon
per million fragments mapped) values (4-OHT versus vehicle) in HFF
MYC-ER control cells and then submitted to analysis using GSEA software
(www.broadinstitute.org/gsea). The list of pre-ranked genes was analysed
with the gene set matrix composed file c2.all.v4.0.symbols.gmt and
c5.all.v4.0.symbols.gmt. Significant gene sets enriched by 4-OHT treatment of
control cells were identified using a false discovery rate q-valueo0.25 and a
nominal P valueo0.05, as defined by http://www.broadinstitute.org/gsea/doc/
GSEAUserGuideFrame.html?Interpreting_GSEA.
RNA-seq. Total RNA (1mg) was spiked with ERCC ExFold RNA spike-In mixes
(Life Technologies). RNA quality was assessed on an Agilent 2100 Bioanalyzer and
samples with a RNA integrity number 48.5 were used. PolyAþ fractions were
purified, randomly fragmented, converted to double-stranded cDNA and processed
through subsequent enzymatic treatments of end repair, dA tailing and ligation to
adaptors following Illumina ‘TruSeq Stranded mRNA Sample Preparation Part
# 15031047 Rev. D’ (this kit incorporates dUTP during second-strand cDNA
synthesis, which implies that only the cDNA strand generated during first-strand
synthesis is eventually sequenced). Adaptor-ligated libraries were generated by PCR
with Illumina PE primers (eight cycles). The resulting purified cDNA libraries were
applied to an Illumina flow cell for cluster generation (TruSeq cluster generation kit
v5) and sequenced on the Genome Analyzer IIx with SBS TruSeq v5 reagents by
following the manufacturer’s protocols.
RNA-Seq data processing. Image analysis and per-cycle base-calling was
performed with Illumina Real Time Analysis software (RTA1.13). Conversion to
FASTQ read format with the ELAND algorithm (v2e) was performed with
CASAVA-1.8 (Illumina). These files contain only reads that passed ‘chastity’
filtering (flagged with a ‘N’, for ‘not filtered’ in the sequence identifier line).
‘Chastity’ parameter measures signal contamination in raw data and allows to
flag unreliable reads. Quality check was done via fastqc (v0.9.4, Babraham
Bioinformatics). Raw reads were aligned to the build version GRCh37/hg19
of the human genome where the sequence of the ERCC synthetic spike-in RNAs
(http://tools.invitrogen.com/downloads/ERCC92.fa) had been added. Tophat5
(version 2.0.4) was used for alignment with the following parameters: --bowtie1,
--max-multihits 5, --genome-read-mismatches 1 --segment-mismatches 1
--segment-length 19 --splice-mismatches 0 --library-type fr-firststrand. Gene
expression levels and synthetic spike-in RNA (FPKM) were quantified with
cufflinks (version 2.0.2), with the following parameters: -N, --library-type
fr-firststrand, -u. Further, we used a loess regression to renormalize the FPKM
values by using only the spike-in values to fit the loess following the strategy
described74. The affy package in R provides a function, loess.normalize, performing
loess regression on a matrix of values and allowing to specify which subset of data
to use when fitting the loess (see the affy package for further details). The result was
a matrix of FPKM values normalized to the control ERCC spike-ins.
RNA-Seq GSEA analysis. Genes were rank-ordered according to the fold change
in FPKM values (4-OHT versus vehicle) in HFF MYC-ER control cells and then
submitted to analysis using GSEA software (www.broadinstitute.org/gsea). The list
of pre-ranked genes was analysed with the gene set matrix composed file
c2.all.v4.0.symbols.gmt and c5.all.v4.0.symbols.gmt. Significant gene sets enriched
by OHT treatment of control cells were identified using a false discovery rate
q-valueo0.25 and a nominal P valueo0.05. All analyses were performed using
GSEA v2.1 software with pre-ranked list and 1000 data permutations.
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Analysis of human genomic tumour data. Gene expression data from 20 studies
profiling human tumours were downloaded from either Oncomine or GEO. The
complete list of data sets, together with their GEO accession numbers, is provided
in Supplementary Data 9. Expression data for each study were converted into the
GenePattern GCT format. To obtain one expression value per gene and sample,
GCT files were subsequently collapsed using the CollapseDataset module in
GenePattern. We next rank-ordered the samples within each data set according to
the mRNA levels of BPTF, c-MYC, N-MYC or L-MYC and performed a ssGSEA to
calculate activation scores for four MYC-dependent gene signatures in each sample.
ssGSEA-enrichment score represents the degree to which the genes in a particular
gene set are coordinately up- or downregulated within a sample. The
following gene signatures were downloaded from Molecular Signature Database:
BILD_MYC_ONCOGENIC_SIGNATURE (M2069), ALFANO_MYC_TARGETS
(M2477) and SCHUHMACHER_MYC_TARGETS_UP. The Seitz signature was
built from the data published in ref. 75.
Statistical analysis. All quantitative data are presented as mean±s.e.m. from Z3
experiments or samples per data point (n is mentioned in each figure legend).
Unpaired Student’s t-test (two-tailed) was used to compare two groups of
independent samples. Paired Student’s t-test (two-tailed) was used to compare
matched pairs samples. To compare the data distribution of two separate
populations without assuming normal distribution, we performed a Wilcoxon
signed-ranked test. For in vitro experiments, sample size required was not
determined a priori. The experiments were not randomized.
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